GTBP

GT Biopharma Inc

GTBP, USA

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advanced solid tumors; and GTB-7550, a product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.

https://www.gtbiopharma.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
GTBP
stock
GTBP

GT Biopharma shares advance as flagship GTB 3650 trial escalates to next dose level MSN

Read more →
GTBP
stock
GTBP

GT Biopharma stock rises as Phase 1 trial advances to higher dose Investing.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$8

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.84

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-103.80 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-72.07 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

High

0.44

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 9.23% of the total shares of GT Biopharma Inc

1.

Bank of Montreal

(2.601%)

since

2025/06/30

2.

BMO Capital Markets Corp.

(2.601%)

since

2025/06/30

3.

Renaissance Technologies Corp

(0.7393%)

since

2025/06/30

4.

Geode Capital Management, LLC

(0.67%)

since

2025/06/30

5.

Fidelity Extended Market Index

(0.3575%)

since

2025/07/31

6.

Advisor Group Holdings, Inc.

(0.322%)

since

2025/06/30

7.

Vanguard Group Inc

(0.2953%)

since

2025/06/30

8.

Wells Fargo & Co

(0.2814%)

since

2025/06/30

9.

BlackRock Inc

(0.2737%)

since

2025/06/30

10.

Vanguard Institutional Extnd Mkt Idx Tr

(0.2028%)

since

2025/07/31

11.

UBS Group AG

(0.1633%)

since

2025/06/30

12.

Spartan Extended Market Index Pool F

(0.1323%)

since

2025/07/31

13.

Morgan Stanley - Brokerage Accounts

(0.1129%)

since

2025/06/30

14.

Fidelity Series Total Market Index

(0.1066%)

since

2025/07/31

15.

Newbridge Financial Services Group, Inc.

(0.0773%)

since

2025/06/30

16.

Fidelity Total Market Index

(0.0617%)

since

2025/07/31

17.

Dimensional US Sustainability Core 1 ETF

(0.0462%)

since

2025/08/29

18.

Extended Equity Market Fund K

(0.0316%)

since

2025/06/30

19.

Hartland & Co

(0.0243%)

since

2025/06/30

20.

Spartan Total Market Index Pool G

(0.0217%)

since

2025/07/31

21.

NT Ext Equity Mkt Idx Fd - NL

(0.017%)

since

2025/06/30

22.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0132%)

since

2025/06/30

23.

Tower Research Capital LLC

(0.0126%)

since

2025/06/30

24.

Northern Trust Extended Eq Market Idx

(0.0109%)

since

2025/06/30

25.

NT Ext Equity Mkt Idx Fd - L

(0.0109%)

since

2025/06/30

26.

JONES FINANCIAL COMPANIES LLLP

(0.0084%)

since

2025/06/30

27.

BNYM Mellon SL Market Completion UC1

(0.008%)

since

2025/06/30

28.

State St US Extended Mkt Indx NL Cl C

(0.0076%)

since

2025/08/31

29.

Extended Equity Market Fund M

(0.004%)

since

2025/06/30

30.

SSgA U.S. Total Market Index Strategy

(0.0032%)

since

2025/03/31

31.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0031%)

since

2025/06/30

32.

State St US Ttl Mkt Indx NL Cl A

(0.0028%)

since

2025/08/31

33.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0026%)

since

2024/12/31

34.

Northern Trust Wilshire 5000

(0.0022%)

since

2025/06/30

35.

Mount Yale Investment Advisors, LLC

(0.0013%)

since

2025/06/30

36.

Bank of America Corp

(0.0008%)

since

2025/06/30

37.

BNP Paribas Arbitrage, SA

(0.0004%)

since

2025/06/30

38.

Blue Bell Private Wealth Management, LLC

(0.0003%)

since

2025/06/30

39.

SBI Securities Co Ltd

(0.0002%)

since

2025/06/30

40.

Front Row Advisors LLC

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.83

EPS Estimate

-0.38

EPS Difference

-0.45

Surprise Percent

-118.4211%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(3)
Value
Undervalued(6.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.